popup

BLAZE-2 US (Cohen), 2021 NCT04497987

bamlanivimab monotherapy vs. placebo

COVID-19 prophylaxis (excluding children)

O'Brien (Part A: uninfected household contacts), 2021 NCT04452318

casirivimab/imdevimab (Ronapreve) vs. placebo

COVID-19 prophylaxis (excluding children)

Isa, 2021 NCT04519437

casirivimab/imdevimab (Ronapreve) vs. placebo

COVID-19 prophylaxis (excluding children)

Cov-2069 (Cohort A: negative SARS-CoV-2 RT-qPCR test result), 2021 NCT04452318

casirivimab/imdevimab (Ronapreve) vs. placebo

COVID-19 prophylaxis (excluding children)

Jurdi, 2022

cilgavimab and tixagevimab (Evusheld) vs. control

COVID-19 prophylaxis (excluding children)

STORM CHASER, 2021 NCT04625972

cilgavimab and tixagevimab (Evusheld) vs. placebo

COVID-19 prophylaxis (excluding children)

PROVENT, 2022 NCT04625725

cilgavimab and tixagevimab (Evusheld) vs. placebo

COVID-19 prophylaxis (excluding children)

Gendelman, 2020

colchicine vs. control

COVID-19 prophylaxis (excluding children)

NCT04390503, 0 NCT04390503

convalescent plasma treatment vs. placebo

COVID-19 prophylaxis (excluding children)

Chandan, 2020

non-steroidal anti-inflammatory drugs vs. control

COVID-19 prophylaxis (excluding children)